Research progress onneoadjuvant therapy in stage IIIA-N2 non-small cell lung cancer

ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. Key words: Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress